| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP3A4 |
| Uniprot No | P08684 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-503aa |
| 氨基酸序列 | ALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA- |
| 预测分子量 | 63.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CYP3A4重组蛋白的参考文献摘要：
---
1. **文献名称**: *"Functional expression of human cytochrome P450 3A4 in Escherichia coli: Importance of redox partner flexibility"*
**作者**: Guengerich FP, et al.
**摘要**: 研究通过在大肠杆菌中重组表达人源CYP3A4蛋白，并探讨不同氧化还原伴侣(如NADPH-P450还原酶和细胞色素b5)对其催化活性的影响，发现伴侣系统的灵活性对维持其代谢活性至关重要。
---
2. **文献名称**: *"Reconstitution of recombinant cytochrome P450 3A4 in nanodiscs for ligand binding and metabolism studies"*
**作者**: Denisov IG, Sligar SG.
**摘要**: 利用纳米盘(nanodisc)技术将重组CYP3A4嵌入类膜环境，成功模拟其在体内的脂质双层结构，显著提高了酶与底物(如睾酮和咪达唑仑)的结合能力及代谢稳定性。
---
3. **文献名称**: *"Baculovirus-mediated expression of human CYP3A4 in insect cells: Role of phosphorylation in enzyme activity"*
**作者**: Yamazaki H, et al.
**摘要**: 通过杆状病毒系统在昆虫细胞中高效表达CYP3A4.发现其磷酸化修饰(如丝氨酸残基)可调控酶对特定药物(如环孢素A)的代谢活性，为研究翻译后修饰对CYP功能的影响提供模型。
---
**备注**：以上文献为示例，实际引用时需核对具体发表信息及原文内容。如需最新研究，建议在PubMed或Web of Science中以“CYP3A4 recombinant protein”为关键词检索。
Cytochrome P450 3A4 (CYP3A4) is a critical enzyme in the cytochrome P450 superfamily, predominantly expressed in the human liver and intestine. It plays a central role in the oxidative metabolism of approximately 50% of clinically used drugs, as well as endogenous compounds and environmental toxins. As a membrane-bound monooxygenase, CYP3A4 requires a redox partner, NADPH-cytochrome P450 reductase, to catalyze reactions, often involving complex substrate recognition due to its large, flexible active site.
Recombinant CYP3A4 proteins are engineered to study its function, drug interactions, and metabolic variability without relying on human tissue samples. These proteins are produced in heterologous systems such as bacteria (E. coli), yeast, insect cells (baculovirus systems), or mammalian cells (e.g., HEK293). Each system offers trade-offs: bacterial systems are cost-effective but lack post-translational modifications, while mammalian systems preserve native enzyme structure and activity at higher production costs.
Challenges in producing functional recombinant CYP3A4 include maintaining stability, proper membrane integration, and interaction with redox partners. Despite this, recombinant CYP3A4 is invaluable for drug development, enabling high-throughput screening of drug candidates, assessing enzyme inhibition/induction, and studying genetic polymorphisms affecting drug response. Structural studies using recombinant proteins (e.g., X-ray crystallography, cryo-EM) have advanced understanding of substrate binding and catalytic mechanisms, guiding rational drug design.
Overall, recombinant CYP3A4 serves as a vital tool in pharmacology and toxicology, bridging in vitro data to clinical outcomes while reducing reliance on animal testing. Its applications extend to personalized medicine, where metabolic variability informs tailored therapies.
×
